Development and evaluation of an inactivated coxsackievirus A16 vaccine in gerbils

References

• Han Z, Song Y, Xiao J, et al. Genomic epidemiology of coxsackievirus A16 in mainland of China, 2000-18. Virus Evol. 2020 Jul;6(2):veaa084.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Zhu Z, Yang W, et al. An emerging recombinant human enterovirus 71 responsible for the 2008 outbreak of hand foot and mouth disease in Fuyang city of China. Virol J. 2010 May;7:94.
   PubMed Web of Science ®Google Scholar
• Xing W, Liao Q, Viboud C, et al. Hand, foot, and mouth disease in China, 2008-12: an epidemiological study. Lancet Infect Dis. 2014;14(4):308–318.
   PubMed Web of Science ®Google Scholar
• Yang B, Liu F, Liao Q, et al. Epidemiology of hand, foot and mouth disease in China, 2008 to 2015 prior to the introduction of EV-A71 vaccine. Euro Surveill. 2017 Dec;22(50):16–00824.
   PubMedGoogle Scholar
• Liu SL, Pan H, Liu P, et al. Comparative epidemiology and virology of fatal and nonfatal cases of hand, foot and mouth disease in mainland China from 2008 to 2014. Rev Med Virol. 2015 Mar;25(2):115–128.
   PubMed Web of Science ®Google Scholar
• Yi L, Zeng H, Zheng H, et al. Molecular surveillance of coxsackievirus A16 in southern China, 2008–2019. Arch Virol. 2021 Jun;166(6):1653–1659.
   PubMed Web of Science ®Google Scholar
• He SJ, Han JF, Ding XX, et al. Characterization of enterovirus 71 and coxsackievirus A16 isolated in hand, foot, and mouth disease patients in guangdong, 2010. Int J Infect Dis. 2013 Nov;17(11):e1025–e1030.
   PubMed Web of Science ®Google Scholar
• Xu W, Liu CF, Yan L, et al. Distribution of enteroviruses in hospitalized children with hand, foot and mouth disease and relationship between pathogens and nervous system complications. Virol J. 2012 Jan;9:8.
   PubMed Web of Science ®Google Scholar
• Hooi YT, Ong KC, Tan SH, et al. Coxsackievirus A16 in a 1-Day-Old mouse model of central nervous system infection shows lower neurovirulence than enterovirus A71. J Comp Pathol. 2020;176:19–32.
   PubMed Web of Science ®Google Scholar
• Hu W, Zhang H, Han Q, et al. A vero-cell-adapted vaccine donor strain of influenza A virus generated by serial passages. Vaccine. 2015 Jan;33(2):374–381.
   PubMed Web of Science ®Google Scholar
• Betáková T, Svetlíková D, Gocník M. Overview of measles and mumps vaccine: origin, present, and future of vaccine production. Acta Virol. 2013;57(2):91–96.
   PubMed Web of Science ®Google Scholar
• Sun YS, Li YJ, Xia Y, et al. Coxsackievirus A16 induced neurological disorders in young gerbils which could serve as a new animal model for vaccine evaluation. Sci Rep. 2016 Sep;6:34299.
   PubMed Web of Science ®Google Scholar
• Yao PP, Miao ZP, Xu F, et al. An adult gerbil model for evaluating potential coxsackievirus A16 vaccine candidates. Vaccine. 2019 Aug;37(36):5341–5349.
   PubMed Web of Science ®Google Scholar
• vZhang Y, Wang D, Yan D, et al. Molecular evidence of persistent epidemic and evolution of subgenotype B1 coxsackievirus A16-associated hand, foot, and mouth disease in China. J Clin Microbiol. 2010 Feb;48(2):619–622.
   PubMed Web of Science ®Google Scholar
• Sun YS, Xu F, An Q, et al. A SARS-CoV-2 variant with the 12-bp deletion at E gene. Emerg Microbes Infect. 2020 Dec;9(1):2361–2367.
   PubMed Web of Science ®Google Scholar
• Arıkan SAN, Özbeyli D, Elmas MA, et al. Effects of moderate aerobic exercise, low-level laser therapy, or their combination on muscles pathology, oxidative stress and irisin levels in the mdx mouse model of Duchenne muscular dystrophy. Lasers Med Sci. 2022 [cited 2022 April 19]: 1–12. doi:10.1007/s10103-022-03562-8.
   Web of Science ®Google Scholar
• Ping J, Lopes TJS, Nidom CA, et al. Development of high-yield influenza A virus vaccine viruses. Nat Commun. 2015 Sep 2;6:8148.
   PubMed Web of Science ®Google Scholar
• Chen Z, Baz M, Lu J, et al. Development of a high-yield live attenuated H7N9 influenza virus vaccine that provides protection against homologous and heterologous H7 wild-type viruses in ferrets. J Virol. 2014 Jun;88(12):7016–7023.
   PubMed Web of Science ®Google Scholar
• Sun T, Liu Y, Zhang Y, et al. Molecular phylogeny of coxsackievirus A16. J Clin Microbiol. 2014 Oct;52(10):3829–3830.
   PubMed Web of Science ®Google Scholar
• Shi J, Huang X, Liu Q, et al. Identification of conserved neutralizing linear epitopes within the VP1 protein of coxsackievirus A16. Vaccine. 2013 Apr;31(17):2130–2136.
   PubMed Web of Science ®Google Scholar
• Zhang C, Yang Y, Chi Y, et al. Hexon-modified recombinant E1-deleted adenoviral vectors as bivalent vaccine carriers for coxsackievirus A16 and enterovirus 71. Vaccine. 2015 Sep;33(39):5087–5094.
   PubMed Web of Science ®Google Scholar
• Ku Z, Liu Q, Ye X, et al. A virus-like particle based bivalent vaccine confers dual protection against enterovirus 71 and coxsackievirus A16 infections in mice. Vaccine. 2014 Jul;32(34):4296–4303.
   PubMed Web of Science ®Google Scholar
• Lin YC, Wu CN, Shih SR, et al. Characterization of a Vero cell-adapted virulent strain of enterovirus 71 suitable for use as a vaccine candidate. Vaccine. 2002 Jun;20(19–20):2485–2493.
   PubMed Web of Science ®Google Scholar
• Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020 Dec;383(27):2603–2615.
   PubMed Web of Science ®Google Scholar
• Jin Y, Hou C, Li Y, et al. mRNA vaccine: How to meet the challenge of SARS-CoV-2. Front Immunol. 2022;12:821538–821538.
   PubMed Web of Science ®Google Scholar
• Chen P, Zhang KH, Na T, et al. The hUC-MSCs cell line CCRC-1 represents a novel, safe and high-yielding HDCs for the production of human viral vaccines. Sci Rep. 2017 Oct;7(1):12484.
   PubMed Web of Science ®Google Scholar
• An W Q, Su Z G, Pan R W, et al. The immunogenicity and protection effect of the BPL-inactivated CA16 vaccine in different animal systems. Hum Vaccin Immunother. 2014;10(3):628–639.
   PubMed Web of Science ®Google Scholar
• Fan S, Liao Y, Jiang G, et al. Efficacy of an inactivated bivalent vaccine for enterovirus 71 and coxsackievirus A16 in mice immunized intradermally. Vaccine. 2021 Jan;39(3):596–604.
   PubMed Web of Science ®Google Scholar
• Ma B, He LF, Zhang YL, et al. Characteristics and viral propagation properties of a new human diploid cell line, Walvax-2, and its suitability as a candidate cell substrate for vaccine production. Hum Vaccin Immunother. 2015;11(4):998–1009.
   PubMed Web of Science ®Google Scholar
• Tsugawa T, Tsutsumi H. Genomic changes detected after serial passages in cell culture of virulent human G1P[8] rotaviruses. Infect Genet Evol. 2016 Nov;45:6–10.
   PubMed Web of Science ®Google Scholar
• Tsugawa T, Tatsumi M, Tsutsumi H. Virulence-associated genome mutations of murine rotavirus identified by alternating serial passages in mice and cell cultures. J Virol. 2014 May;88(10):5543–5558.
   PubMed Web of Science ®Google Scholar
• Mao Q, Wang Y, Gao R, et al. A neonatal mouse model of coxsackievirus A16 for vaccine evaluation. J Virol. 2012 Nov;86(22):11967–11976.
   PubMed Web of Science ®Google Scholar
• Wang J, Zhang Y, Zhang X, et al. Pathologic and immunologic characteristics of coxsackievirus A16 infection in rhesus macaques. Virology. 2017 Jan;500:198–208.
   PubMed Web of Science ®Google Scholar
• Wei Y, Hong Q, Chen D, et al. Permissibility of Mongolian gerbil for Angiostrongylus cantonensis infection and utility of this animal model for anthelmintic studies. Parasitol Res. 2014 May;113(5):1687–1693.
   PubMed Web of Science ®Google Scholar
• Hanafi HA, Fryauff DJ, Kittell CE. Evaluation of the fat-tailed gerbil, Pachyuromys duprasi (Rodentia: Gerbillidae), as a new animal model for studies of Leishmania major infection and transmission. Vector Borne Zoonotic Dis. 2013 Sep;13(9):650–656.
   PubMed Web of Science ®Google Scholar